| . | Comparisons . | |
|---|---|---|
| Analysis . | Reduced-Dose TMP-SMX, mg/kg/d | Standard-Dose TMP-SMX, mg/kg/d |
| Comparative cohorts: mortality | Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: <15 | Kosaka et al. [11]: 15–20 Nakashima et al. [12]: 10–20 Ohmura et al. [13]: 15–20 |
| Comparative cohorts: adverse events | Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: <15 | Kosaka et al. [11]: 15–20 Nakashima et al. [12]: 10–20 Ohmura et al. [13]: 15–20 |
| Reduced-dose cohorts only: mortality | Cohorts reporting on TMP-SMX for PJP at a dose less than 15 mg/kg/d: Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: 4–10 Sattler et al. [17]: mean 12 Thomas et al. [18]: median 9.7 Yang et al. [19]: median 14.4 | Historical cohorts of RCTs reporting on TMP-SMX therapy for PJP: Gagnon et al. [20]: 15 Klein et al. [21]: 20 Medina et al. [5]: 20 Saffrin et al. [22]: 12–20 Sattler et al. [23]: 20 Toma et al. [24]: >16 Toma et al. [25]: >16 Wharton et al. [26]: 20 |
| . | Comparisons . | |
|---|---|---|
| Analysis . | Reduced-Dose TMP-SMX, mg/kg/d | Standard-Dose TMP-SMX, mg/kg/d |
| Comparative cohorts: mortality | Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: <15 | Kosaka et al. [11]: 15–20 Nakashima et al. [12]: 10–20 Ohmura et al. [13]: 15–20 |
| Comparative cohorts: adverse events | Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: <15 | Kosaka et al. [11]: 15–20 Nakashima et al. [12]: 10–20 Ohmura et al. [13]: 15–20 |
| Reduced-dose cohorts only: mortality | Cohorts reporting on TMP-SMX for PJP at a dose less than 15 mg/kg/d: Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: 4–10 Sattler et al. [17]: mean 12 Thomas et al. [18]: median 9.7 Yang et al. [19]: median 14.4 | Historical cohorts of RCTs reporting on TMP-SMX therapy for PJP: Gagnon et al. [20]: 15 Klein et al. [21]: 20 Medina et al. [5]: 20 Saffrin et al. [22]: 12–20 Sattler et al. [23]: 20 Toma et al. [24]: >16 Toma et al. [25]: >16 Wharton et al. [26]: 20 |
Abbreviations: PJP, Pneumocystis carinii pneumonia; RCT, randomized controlled trial; TMP-SMX, trimethoprim-sulfamethoxazole.
| . | Comparisons . | |
|---|---|---|
| Analysis . | Reduced-Dose TMP-SMX, mg/kg/d | Standard-Dose TMP-SMX, mg/kg/d |
| Comparative cohorts: mortality | Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: <15 | Kosaka et al. [11]: 15–20 Nakashima et al. [12]: 10–20 Ohmura et al. [13]: 15–20 |
| Comparative cohorts: adverse events | Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: <15 | Kosaka et al. [11]: 15–20 Nakashima et al. [12]: 10–20 Ohmura et al. [13]: 15–20 |
| Reduced-dose cohorts only: mortality | Cohorts reporting on TMP-SMX for PJP at a dose less than 15 mg/kg/d: Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: 4–10 Sattler et al. [17]: mean 12 Thomas et al. [18]: median 9.7 Yang et al. [19]: median 14.4 | Historical cohorts of RCTs reporting on TMP-SMX therapy for PJP: Gagnon et al. [20]: 15 Klein et al. [21]: 20 Medina et al. [5]: 20 Saffrin et al. [22]: 12–20 Sattler et al. [23]: 20 Toma et al. [24]: >16 Toma et al. [25]: >16 Wharton et al. [26]: 20 |
| . | Comparisons . | |
|---|---|---|
| Analysis . | Reduced-Dose TMP-SMX, mg/kg/d | Standard-Dose TMP-SMX, mg/kg/d |
| Comparative cohorts: mortality | Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: <15 | Kosaka et al. [11]: 15–20 Nakashima et al. [12]: 10–20 Ohmura et al. [13]: 15–20 |
| Comparative cohorts: adverse events | Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: <15 | Kosaka et al. [11]: 15–20 Nakashima et al. [12]: 10–20 Ohmura et al. [13]: 15–20 |
| Reduced-dose cohorts only: mortality | Cohorts reporting on TMP-SMX for PJP at a dose less than 15 mg/kg/d: Kosaka et al. [11]: <15 Nakashima et al. [12]: 4–10 Ohmura et al. [13]: 4–10 Sattler et al. [17]: mean 12 Thomas et al. [18]: median 9.7 Yang et al. [19]: median 14.4 | Historical cohorts of RCTs reporting on TMP-SMX therapy for PJP: Gagnon et al. [20]: 15 Klein et al. [21]: 20 Medina et al. [5]: 20 Saffrin et al. [22]: 12–20 Sattler et al. [23]: 20 Toma et al. [24]: >16 Toma et al. [25]: >16 Wharton et al. [26]: 20 |
Abbreviations: PJP, Pneumocystis carinii pneumonia; RCT, randomized controlled trial; TMP-SMX, trimethoprim-sulfamethoxazole.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
